fluoxetine has been researched along with Hypertension, Pulmonary in 27 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of the selective serotonin reuptake inhibitor (SSRI) fluoxetine on extracellular matrix (ECM) remodeling of the pulmonary artery and inflammation of the lungs in pulmonary arterial hypertension (PAH) induced by monocrotaline in rats." | 7.77 | Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats. ( Han, DD; Li, XQ; Wang, HL; Wang, HM; Yang, CG; Zhang, XH, 2011) |
| " As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0." | 7.74 | Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. ( Belik, J; Fornaro, E; Li, D; Pan, J, 2007) |
| "There is no conclusive evidence for increased risk for malformations but paroxetine and possibly fluoxetine use in early pregnancy may be associated with a small increased risk for cardiovascular malformations." | 4.86 | Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). ( Ellfolk, M; Malm, H, 2010) |
| "To investigate the effect of fluoxetine on neurite growth inhibitor (Nogo) expession and collagen production of cardiac tissue in rats with right heart failure and pulmonary hypertension." | 3.83 | [Effects of Fluoxetine on Nogo Expression and Collagen Production with Decrease of Pulmonary Artery Pressure in Rats with Right Ventricular Failure.] ( Chen, YC; Nie, H; Ran, X; Zhao, JX, 2016) |
| "Blockade of the serotonin reuptake transporter (5-HTT), using fluoxetine, has been identified as a potential therapeutic target for preventing and, importantly, reversing pulmonary hypertension (PH)." | 3.79 | Assessment of the serotonin pathway as a therapeutic target for pulmonary hypertension. ( Fujii, Y; Gray, EA; Pearson, JT; Schwenke, DO; Shirai, M; Sonobe, T; Tsuchimochi, H; Umetani, K; Yoshimoto, M, 2013) |
| "The selective serotonin re-uptake inhibitor fluoxetine has been shown to protect against monocrotaline (MCT)-induced pulmonary hypertension in rats." | 3.78 | Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor. ( Han, DD; Liu, JR; Wang, HL; Wang, Y; Zhang, XH, 2012) |
| "To investigate the effects of the selective serotonin reuptake inhibitor (SSRI) fluoxetine on extracellular matrix (ECM) remodeling of the pulmonary artery and inflammation of the lungs in pulmonary arterial hypertension (PAH) induced by monocrotaline in rats." | 3.77 | Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats. ( Han, DD; Li, XQ; Wang, HL; Wang, HM; Yang, CG; Zhang, XH, 2011) |
| " As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0." | 3.74 | Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. ( Belik, J; Fornaro, E; Li, D; Pan, J, 2007) |
| " During exposure to hypoxia (10% O2 for 2 weeks), the animals received one of the specific 5-HTT inhibitors citalopram and fluoxetine (10 mg/kg/day), the selective 5-HT1B/1D receptor antagonist GR127935 (2 and 10 mg/kg/day), or the 5-HT2A receptor antagonist ketanserin (2 mg/kg/day)." | 3.72 | Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. ( Adnot, S; Eddahibi, S; Hamon, M; Marcos, E; Nosjean, A; Pham, MH; Raffestin, B, 2003) |
| "Treatment of rats with monocrotaline (MCT) leads to pulmonary hypertension, right ventricular (RV) hypertrophy, and finally to RV heart failure." | 3.71 | Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac beta-adrenoceptor system in experimental heart failure. ( Beilfuss, A; Brandt, K; Brodde, OE; Heinroth-Hoffmann, I; Leineweber, K; Pönicke, K; Wludyka, B, 2002) |
| "Depression has a female sex predilection with 2 to 3% of the pregnant women population presently requiring treatment with selective serotonin reuptake inhibitors (SSRI)." | 2.44 | Fetal and neonatal effects of maternal drug treatment for depression. ( Belik, J, 2008) |
| "Fluoxetine was administered by gastric gavage once a day for 21 d." | 1.38 | Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats. ( Bai, Y; Liu, M; Sun, YX; Wang, HL; Wang, HM; Wang, Y; Zhang, XH, 2012) |
| "Pretreatment with fasudil, a Rho kinase inhibitor, blunted the effects of 5-HT infusion." | 1.37 | Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus. ( Abman, SH; Delaney, C; Gien, J; Grover, TR; Roe, G, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 12 (44.44) | 29.6817 |
| 2010's | 14 (51.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ran, X | 1 |
| Zhao, JX | 1 |
| Nie, H | 1 |
| Chen, YC | 1 |
| Song, ZH | 1 |
| Wang, HM | 4 |
| Liu, M | 3 |
| Bai, Y | 3 |
| Wang, Y | 5 |
| Wang, HL | 7 |
| Houssaini, A | 1 |
| Abid, S | 1 |
| Mouraret, N | 1 |
| Wan, F | 1 |
| Rideau, D | 2 |
| Saker, M | 1 |
| Marcos, E | 2 |
| Tissot, CM | 1 |
| Dubois-Randé, JL | 1 |
| Amsellem, V | 1 |
| Adnot, S | 5 |
| Gray, EA | 1 |
| Tsuchimochi, H | 1 |
| Pearson, JT | 1 |
| Sonobe, T | 1 |
| Fujii, Y | 1 |
| Yoshimoto, M | 1 |
| Umetani, K | 1 |
| Shirai, M | 1 |
| Schwenke, DO | 1 |
| Lopes, LM | 1 |
| Carrilho, MC | 1 |
| Francisco, RP | 1 |
| Lopes, MA | 1 |
| Krebs, VL | 1 |
| Zugaib, M | 1 |
| Jayarajan, RN | 1 |
| Shere, S | 1 |
| Sutar, R | 1 |
| Karmani, S | 1 |
| Reddi, VS | 1 |
| Kesavan, M | 1 |
| Viswanath, B | 1 |
| Jain, S | 1 |
| Kowal-Bielecka, O | 1 |
| Fransen, J | 1 |
| Avouac, J | 1 |
| Becker, M | 1 |
| Kulak, A | 1 |
| Allanore, Y | 1 |
| Distler, O | 1 |
| Clements, P | 1 |
| Cutolo, M | 1 |
| Czirjak, L | 1 |
| Damjanov, N | 1 |
| Del Galdo, F | 1 |
| Denton, CP | 1 |
| Distler, JHW | 1 |
| Foeldvari, I | 1 |
| Figelstone, K | 1 |
| Frerix, M | 1 |
| Furst, DE | 1 |
| Guiducci, S | 1 |
| Hunzelmann, N | 1 |
| Khanna, D | 1 |
| Matucci-Cerinic, M | 1 |
| Herrick, AL | 1 |
| van den Hoogen, F | 1 |
| van Laar, JM | 1 |
| Riemekasten, G | 1 |
| Silver, R | 1 |
| Smith, V | 1 |
| Sulli, A | 1 |
| Tarner, I | 1 |
| Tyndall, A | 1 |
| Welling, J | 1 |
| Wigley, F | 1 |
| Valentini, G | 1 |
| Walker, UA | 1 |
| Zulian, F | 1 |
| Müller-Ladner, U | 1 |
| Belik, J | 2 |
| Zhai, FG | 1 |
| Zhang, XH | 6 |
| Zhu, SP | 1 |
| Mao, ZF | 1 |
| Huang, J | 1 |
| Wang, JY | 1 |
| Guignabert, C | 2 |
| Tu, L | 1 |
| Izikki, M | 1 |
| Dewachter, L | 2 |
| Zadigue, P | 2 |
| Humbert, M | 2 |
| Fadel, E | 2 |
| Eddahibi, S | 4 |
| Ellfolk, M | 1 |
| Malm, H | 1 |
| Li, XQ | 1 |
| Yang, CG | 1 |
| Han, DD | 2 |
| Delaney, C | 1 |
| Gien, J | 1 |
| Grover, TR | 1 |
| Roe, G | 1 |
| Abman, SH | 1 |
| Liu, JR | 1 |
| Sun, YX | 2 |
| Leineweber, K | 1 |
| Brandt, K | 1 |
| Wludyka, B | 1 |
| Beilfuss, A | 1 |
| Pönicke, K | 1 |
| Heinroth-Hoffmann, I | 1 |
| Brodde, OE | 1 |
| Pham, MH | 1 |
| Nosjean, A | 1 |
| Raffestin, B | 2 |
| Hamon, M | 3 |
| Rezaie-Majd, S | 1 |
| Murar, J | 1 |
| Nelson, DP | 1 |
| Kelly, RF | 1 |
| Hong, Z | 1 |
| Lang, IM | 1 |
| Varghese, A | 1 |
| Weir, EK | 1 |
| Benferhat, R | 1 |
| Raoul, W | 1 |
| Archer, SL | 1 |
| Michelakis, ED | 1 |
| Maitre, B | 1 |
| Barlier-Mur, AM | 1 |
| Simonneau, G | 1 |
| Naeije, R | 1 |
| Ceylan, ME | 1 |
| Alpsan, MH | 1 |
| Fornaro, E | 1 |
| Li, D | 1 |
| Pan, J | 1 |
| Anchors, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aiming to Reduce Disease-related Gastrointestinal Symptoms in Systemic Sclerosis by Repeat Intestinal Infusions of Anaerobic Cultivated Human Intestinal Microbiome (ACHIM); a Randomized, Double-blind Placebo-controlled 20 Week Study[NCT04300426] | Phase 2 | 75 participants (Actual) | Interventional | 2020-09-24 | Completed | ||
| "Effect of a Pulmonary Rehabilitation Program in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis on Oxygen Consumption, Functionality, and Quality of Life"[NCT06105073] | 67 participants (Anticipated) | Observational [Patient Registry] | 2022-03-01 | Recruiting | |||
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for fluoxetine and Hypertension, Pulmonary
| Article | Year |
|---|---|
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Update of EULAR recommendations for the treatment of systemic sclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Delphi Technique; Endothelin Receptor Antagonists; Europe; | 2017 |
Fetal and neonatal effects of maternal drug treatment for depression.
Topics: Animals; Depression; Female; Fetal Diseases; Fluoxetine; Gastrointestinal Diseases; Humans; Hyperten | 2008 |
Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs).
Topics: Adult; Breast Feeding; Cardiovascular Abnormalities; Congenital Abnormalities; Female; Fluoxetine; H | 2010 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Calcium Channel Blockers; Comorbidity; Dichloroacetic | 2006 |
23 other studies available for fluoxetine and Hypertension, Pulmonary
| Article | Year |
|---|---|
[Effects of Fluoxetine on Nogo Expression and Collagen Production with Decrease of Pulmonary Artery Pressure in Rats with Right Ventricular Failure.]
Topics: Animals; Collagen; Fluoxetine; Heart Failure; Hypertension, Pulmonary; Male; Nogo Proteins; Pulmonar | 2016 |
Involvement of S100A4/Mts1 and associated proteins in the protective effect of fluoxetine against MCT - Induced pulmonary hypertension in rats.
Topics: Animals; Dose-Response Relationship, Drug; Fluoxetine; Hypertension, Pulmonary; Male; Monocrotaline; | 2018 |
Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.
Topics: Animals; Apoptosis; Benzamides; Cell Proliferation; Cells, Cultured; Fluoxetine; Glycogen Synthase K | 2013 |
Assessment of the serotonin pathway as a therapeutic target for pulmonary hypertension.
Topics: Acetylcholine; Angiography; Animals; Disease Models, Animal; Endothelium, Vascular; Fluoxetine; Huma | 2013 |
Fetal ductus arteriosus constriction and closure: analysis of the causes and perinatal outcome related to 45 consecutive cases.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Flow Velocity; Caffeine; Central N | 2016 |
Fluoxetine-induced pulmonary hypertension in a patient with schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Fluoxetine; Humans; Hypertension, Pulmonary | 2014 |
Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Disease Models, Animal; Dose-Response Rel | 2009 |
Continuous fluoxetine administration prevents recurrence of pulmonary arterial hypertension and prolongs survival in rats.
Topics: Animals; Blotting, Western; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Hy | 2009 |
Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter.
Topics: Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Dichloroacetic Acid; Female; Fluoxetine; Ge | 2009 |
Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats.
Topics: Animals; Cytokines; Disease Models, Animal; Extracellular Matrix; Familial Primary Pulmonary Hyperte | 2011 |
Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Topics: Animals; Apoptosis; beta Catenin; Blood Pressure; Bone Morphogenetic Protein Receptors, Type II; Cas | 2011 |
Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Dose-Response Relationship, Drug; Female; Fe | 2011 |
Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
Topics: Animals; Antihypertensive Agents; Cell Proliferation; Disease Models, Animal; Fluoxetine; Hemodynami | 2012 |
Fluoxetine attenuates chronic methamphetamine-induced pulmonary arterial remodelling: possible involvement of serotonin transporter and serotonin 1B receptor.
Topics: Amphetamine-Related Disorders; Animals; Antidepressive Agents, Second-Generation; Down-Regulation; F | 2013 |
Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats.
Topics: Airway Remodeling; Animals; Disease Models, Animal; Down-Regulation; Familial Primary Pulmonary Hype | 2012 |
Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac beta-adrenoceptor system in experimental heart failure.
Topics: Animals; Binding, Competitive; Cell Membrane; Disease Models, Animal; Eye Proteins; Fluoxetine; G-Pr | 2002 |
Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.
Topics: Analysis of Variance; Animals; Carrier Proteins; Chronic Disease; Citalopram; Disease Models, Animal | 2003 |
Increased release of serotonin from rat ileum due to dexfenfluramine.
Topics: 4-Aminopyridine; Animals; Caffeine; Calcium; Chromatography, High Pressure Liquid; Cytosol; Dexfenfl | 2004 |
Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats.
Topics: Animals; Cell Proliferation; Fluoxetine; Hypertension, Pulmonary; Lung; Monocrotaline; Muscle, Smoot | 2005 |
Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension.
Topics: Angiopoietin-1; Aspartic Acid Endopeptidases; Blotting, Western; Endothelial Cells; Endothelin-1; En | 2006 |
Pulmonary hypertension during lithium therapy: clinical case study.
Topics: Antimanic Agents; Bipolar Disorder; Diagnosis, Differential; Drug Therapy, Combination; Echocardiogr | 2007 |
Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.
Topics: Animals; Antidepressive Agents, Second-Generation; Female; Fetal Diseases; Fluoxetine; Gestational A | 2007 |
Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity.
Topics: Appetite Depressants; Fenfluramine; Fluoxetine; Humans; Hypertension, Pulmonary; Obesity; Selective | 1997 |